FindTrial
Sign In

Urelumab

DRUG8 trials

Sponsors

Bristol-Myers Squibb, M.D. Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Chicago

Conditions

Advanced B-cell NHLAdvanced Solid TumorsB-Cell MalignanciesCancerColorectal CancerHead and Neck CancerLeukemiaMalignant Tumors

Phase 1

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
CompletedNCT01775631
Bristol-Myers SquibbB-Cell Malignancies
Start: 2013-03-31End: 2016-08-31Updated: 2017-03-31
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
CompletedNCT02110082
Bristol-Myers SquibbColorectal Cancer, Head and Neck Cancer
Start: 2014-04-30End: 2016-12-31Updated: 2017-04-19
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
CompletedNCT02252263
Bristol-Myers SquibbMultiple Myeloma
Start: 2014-12-09End: 2017-10-10Updated: 2017-11-01
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
TerminatedNCT02253992
Bristol-Myers SquibbAdvanced B-cell NHL, Advanced Solid Tumors
Start: 2014-09-29End: 2019-05-24Updated: 2020-10-05
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
CompletedNCT02534506
Bristol-Myers SquibbMalignant Tumors
Start: 2015-11-06End: 2016-11-11Target: 18Updated: 2020-05-18
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
CompletedNCT03431948
University of ChicagoCancer
Start: 2018-03-15End: 2022-04-11Updated: 2023-02-16

Phase 2

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
WithdrawnNCT02420938
M.D. Anderson Cancer CenterLeukemia
Start: 2015-07-31Updated: 2016-12-06
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Active, not recruitingNCT02451982
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2016-03-28End: 2026-05-31Target: 76Updated: 2025-12-03

Related Papers

Supplementary Data File 2 from Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment
2025-11-03
The impact of <i>KRAS</i> mutations on the clinical outcome and immune response following immunotherapy for pancreatic cancer.
2024-06-012 citations
Abstract 1159: Machine learning integrating spatial omics uncovers humoral immunity patterns in intratumoral tertiary lymphoid structures in pancreatic cancer pathologic responders
Cancer Research2024-03-221 citations
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2024-03-0123 citations
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
2023-06-2063 citations
Abstract 3241: Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy
Cancer Research2023-04-04
Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.
Journal of Clinical Oncology2022-01-199 citations
812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
2020-11-018 citations
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
American Journal of Hematology2020-02-1395 citations
Trial in progress: Platform phase 1 study investigating the safety of stereotactic body radiotherapy with immuno-oncology agents for the treatment of multiple metastases in advanced solid tumors.
Journal of Clinical Oncology2018-05-20
Oncologist to stand against prime minister in general election
BMJ2014-09-11